logo

Vanda Pharmaceuticals (VNDA)



Trade VNDA now with
  Date
  Headline
8/21/2019 7:07:44 AM Vanda Pharma Names Aranthan Jones As Chief Corporate Affairs And Communications Officer
8/19/2019 7:04:57 AM Vanda Pharma FDA Update For HETLIOZ; Receive CRL From FDA
7/22/2019 7:05:05 AM Vanda Pharma Issues FDA Update For HETLIOZ In Treatment Of Jet Lag Disorder
5/1/2019 4:15:38 PM Vanda Pharma Q1 Loss/share $0.01 Vs. Profit $0.06 Year Ago
4/24/2019 4:32:11 PM Vanda Pharmaceuticals Appoints Phaedra Chrousos To Board Of Directors
2/13/2019 4:06:18 PM Vanda Pharmaceuticals Q4 EPS $0.19 Vs. Loss $0.04 Year Ago
12/20/2018 7:07:07 AM Vanda Pharma: FDA Accepts HETLIOZ SNDA For Review In Treatment Of Jet Lag Disorder
12/10/2018 7:05:37 AM Vanda Announces Positive Pivotal Study Results For HETLIOZ In Patients With Smith-Magenis Syndrome
12/3/2018 6:07:08 AM Vanda Says Tradipitant Met Primary Endpoint In VLY686-2301 Phase II Clinical Study
11/1/2018 9:41:47 AM Vanda Gets FDA Letter Regarding Corporate Webpage
  
 
>